Rationale for targeting the Ras/MAPK pathway in triple-negative breast cancer

Area of Science:

• Oncology
• Cancer Biology
• Molecular Targeted Therapy

Background:

• Triple negative breast cancer (TNBC) is an aggressive subtype lacking specific therapeutic targets.
• TNBC disproportionately affects young minority women, leading to high rates of recurrence and mortality.
• The Ras/MAPK pathway is a potential therapeutic target in TNBC, despite infrequent canonical mutations.

Purpose of the Study:

• To review preclinical and clinical evidence for Ras/MAPK pathway inhibitors in TNBC.
• To explore the potential of neoadjuvant targeted therapy for TNBC.
• To discuss challenges and opportunities in targeting the Ras/MAPK pathway for TNBC treatment.

Main Methods:

• Review of preclinical studies on Ras/MAPK pathway targeting in TNBC.
• Analysis of clinical trial data for Ras/MAPK inhibitors in TNBC.
• Discussion of genomic data (e.g., The Cancer Genome Atlas) regarding pathway mutations.

Main Results:

• Preclinical data suggest Ras/MAPK pathway inhibition is a viable strategy for TNBC.
• Neoadjuvant targeted therapy may improve outcomes by addressing micrometastatic disease.
• Despite infrequent mutations, pathway dysregulation may still be targetable.

Conclusions:

• Targeting the Ras/MAPK pathway represents a promising therapeutic avenue for TNBC.
• Neoadjuvant therapy with Ras/MAPK inhibitors could reduce TNBC recurrence and mortality.
• Further research is needed to overcome obstacles and optimize this targeted approach.